Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1804 - Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2- metastatic breast cancer. (Chloe trial)


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Tadahiko Shien


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


T. Shien1, A. Shimomura2, Y. Uemura3, H. Kato4, M. Kitada5, Y. Kikawa6, E. Shiba7, T. Yoshida8, T. Morimoto9, T. Toyama10, T. Aihara11, H. Mukai12

Author affiliations

  • 1 Breast And Endocrine Surgery, Okayama University Hospital, 700-8558 - Okayama/JP
  • 2 Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Biostatistics, Clinical Research Support Center, Tokyo University Hospital, Tokyo/JP
  • 4 Thoracic Surgery, Teine Keijinkai Hospital, Sapporo/JP
  • 5 Surgery, Asahikawa Medical University, Asahikawa/JP
  • 6 Breast Surgery, Kobe City Medical Center General Hospital, Kobe/JP
  • 7 Surgery, Osaka Breast Clinic, Osaka/JP
  • 8 Breast And Endocrine Surgery, Kanagawa Cancer Center, Kanagawa/JP
  • 9 Breast Surgery, Yao Municipal Hospital, Osaka/JP
  • 10 Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 46708601 - Nagoya/JP
  • 11 Surgery, Keimeikai-Aihara Hospital, Osaka/JP
  • 12 Breast And Medical Oncology, National Cancer Center Hospital East, Kashiwa/JP


Abstract 1804


BOLERO-2 trial demonstrated that the mTOR inhibitor everolimus was effective in overcoming resistance to endocrine therapy, and BOLERO-4 trial is evaluating the efficacy and safety of combined use of everolimus with letrozole as initial therapy for ER positive HER2 negative metastatic breast cancer (MBC). However, there is no study to evaluate the efficacy of everolimus which can prolong the administration period of aromatase inhibitor (AI) through postponing the acquisition of drug-resistance for MBC with sensitivity to aromatase inhibitor.

Trial design

This study is conducted to examine whether additional administration of everolimus significantly prolongs progression-free survival period in post-menopausal patients with ER-positive HER2-negative MBC which have sensitivity to AI. The inclusion criteria are MBC pts with histologically confirmed ER positive and HER2 negative invasive breast cancer with one or more measurable distant metastatic lesions diagnosed by radiological examination. All patients are receiving AI as the first line hormone therapy for 5-7 months. The pts who are sensitive to AI are randomized to everolimus plus AI arm or the AI alone arm. After randomization, the same AI are continued until progression of diseases and next appropriate regimens are started after that. The primary endpoint is the progression free survival, and the secondary endpoints are overall survival, response rate, disease control rate, adverse events, time to treatment failure and the proportion of patients who continued administration of AI agents for 1 year after the randomized allocation. Sample size for randomized pts was determined to attain at least 80% of power to detect a 5.4 months’ difference (10 vs. 15.4 months, HR:0.65) with one-sided alpha of 0.1. Enrollment of 130 pts for randomization is planned over a 2-year accrual period from April 2017.

Clinical trial identification

This trial was registered at UMIN-CTR[umin.ac.jp/ctr/] as UMIN 000025156.

Legal entity responsible for the study

Comprehensive Support Project for Oncological Research of Breast Cancer




T. Toyama: Research funds from Novartis, Kyowa Hakko Kirin, Diichi Sankyo, Ezai, Chugai, Hippon Kayaku and Takeda Co. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.